The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Newlink Genetics Corp | Com | 651511107 | 1,704 | 77,437 | SH | SOLE | 77,437 | 0 | 0 | ||
| Medivation, Inc. | Com | 58501N101 | 158,535 | 2,484,101 | SH | SOLE | 2,484,101 | 0 | 0 | ||
| Sequenom Inc. | Com New | 817337405 | 2,073 | 893,600 | SH | SOLE | 893,600 | 0 | 0 | ||
| Keryx Biopharmaceuticals Inc. | Com | 492515101 | 2,592 | 200,000 | SH | SOLE | 200,000 | 0 | 0 | ||
| Echo Therapeutics Inc. | Com New | 27876L206 | 140 | 44,445 | SH | SOLE | 44,445 | 0 | 0 | ||
| Ampio Pharmaceuticals Inc. | Com | 03209T109 | 14,452 | 2,026,998 | SH | SOLE | 2,026,998 | 0 | 0 | ||
| Vivus Inc. | Call | 928551900 | 1,050 | 5,000 | SH | Call | SOLE | 5,000 | 0 | 0 | |
| Alcobra Ltd | SHS | M2239P109 | 12,366 | 687,000 | SH | SOLE | 687,000 | 0 | 0 | ||
| Inovio Pharmaceuticals Inc. | CPM | 45773H102 | 1,167 | 408,352 | SH | SOLE | 408,352 | 0 | 0 | ||
| Advaxis Inc. | COM NEW | 7624208 | 947 | 225,000 | SH | SOLE | 225,000 | 0 | 0 | ||
| Advaxis Inc. | W EXP 07/15/201 | 7624117 | 186 | 112,500 | SH | SOLE | 112,500 | 0 | 0 | ||
| Parkervision Inc. | COM | 701354102 | 910 | 200,000 | SH | SOLE | 200,000 | 0 | 0 | ||
| Merrimack Pharmaceuticals Inc. | COM | 590328100 | 400 | 75,000 | SH | SOLE | 75,000 | 0 | 0 | ||
| Synthetic Biologics Inc. | COM | 87164U102 | 2,054 | 1,360,000 | SH | SOLE | 1,360,000 | 0 | 0 | ||